Prime Medicine, Inc. Common Stock PRME
Analyst Ratings
- Consensus
- Buy — 5 Buy · 1 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $7.54 (+89.0% upside)
Key Stats
- Today's Range
- $3.54 – $4.14
- 50-Day Range
- $2.72 – $4.14
- 52-Week Range
- $2.67 – $6.94
- Volume
- 8.07 million shs
- Average Volume
- 4.07 million shs
- Market Cap
- $723.69 million
- P/E Ratio
- —
- Dividend Yield
- 80.20%
Dividend
- Dividend Yield
- 80.20%
- Annual Dividend
- $3.20
- Payout Ratio
- —
- Ex-Dividend Date
- 2019-09-10
Short Interest
- Short Interest
- 0.00%
- Days to Cover
- 2.77
About Prime Medicine, Inc. Common Stock
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Related Stocks
Compare head-to-head: PRME vs AMGN·PRME vs MRNA·PRME vs HALO·PRME vs IBRX
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.